Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical (NYSE: RBOT) announced a registered direct offering and concurrent private placement expected to raise approximately $5.9 million gross proceeds. The company agreed to sell 1,150,000 shares of Class A common stock (or pre-funded warrants) at a combined effective price of $5.10 per share with accompanying warrants. Pre-funded warrants are priced at $5.0999. The private placement will issue Series A and Series B common warrants to purchase up to 1,150,000 shares each (total up to 2,300,000 shares) at a $5.10 exercise price, exercisable upon stockholder approval and expiring five years after approval. Series B warrants include a repurchase provision at $0.01 per underlying share upon specified stock-price/volume milestones. Lake Street Capital Markets is the placement agent. Closing expected on or about October 9, 2025, subject to customary conditions and NYSE authorization. Proceeds intended for general corporate purposes.
Vicarious Surgical (NYSE:RBOT) has appointed Joseph Doherty as Chairman of the Board of Directors. Doherty, who joined the board in June 2025, brings extensive healthcare and medical device industry experience, having served as CEO of Worcester City Campus Corporation and President of Scapa Healthcare.
His background includes leadership roles at Olympus Surgical Technologies America and a 24-year tenure at Johnson & Johnson, where he served as Vice President of Integration and Transformation. Doherty holds a BS in Engineering from West Point and an MBA from Nichols College.
Vicarious Surgical (NYSE:RBOT), a next-generation robotics technology company focused on transforming robotic surgery, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company's management team will deliver a presentation on Wednesday, September 10, 2025 at 9:00 a.m. ET. Investors and interested parties can access the live audio webcast through the Events & Presentations section of Vicarious Surgical's investor relations website.
Vicarious Surgical (NYSE: RBOT) reported its Q2 2025 financial results, marking a significant transition in leadership as Adam Sachs moves to President and Stephen From takes over as CEO. The surgical robotics company reported a GAAP net loss of $13.2 million ($2.23 per share), improving from a $15.2 million loss in Q2 2024.
Operating expenses decreased 24% to $13.5 million, with R&D expenses at $9.1 million, G&A at $4.1 million, and sales/marketing at $0.3 million. The company ended Q2 with $24.0 million in cash and investments, reporting a quarterly cash burn of $13.4 million. Management projects full-year 2025 cash burn of approximately $50 million.
[ "Net loss improved from $15.2M in Q2 2024 to $13.2M in Q2 2025", "Operating expenses reduced by 24% year-over-year", "Sales and marketing expenses decreased significantly from $1.2M to $0.3M" ]Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.
From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.
As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.
Vicarious Surgical (NYSE: RBOT), a next-generation robotics technology company focused on transforming robotic surgery, has scheduled its Q2 2025 financial results announcement for August 12, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can join via phone using the following details: domestic callers: +1 833-470-1428, international callers: +1 404-975-4839, access code: 572850. A webcast will be available on the company's investor relations website.
Vicarious Surgical (NYSE: RBOT) has announced a strategic collaboration with UMass Memorial Medical Center, the largest not-for-profit hospital in Central Massachusetts. The partnership aims to support the adoption and utilization of Vicarious Surgical's robotic surgery system through various initiatives.
The collaboration will focus on streamlining operational aspects including inventory management, sterilization protocols, and standardization of pre and post-procedure processes. It will also encompass case observation for surgeons, system testing, research development insights, peer-to-peer education, and best practices promotion.
UMass Memorial Medical Center, with 826 licensed beds, serves as the clinical partner of the University of Massachusetts Chan Medical School and will work directly with Vicarious Surgical's team to refine and validate best practices in robotic surgery.
Vicarious Surgical (NYSE: RBOT) has announced its upcoming first quarter 2025 financial results release, scheduled for May 12, 2025, after market close. The company, which specializes in next-generation robotics technology for surgical applications, will discuss its financial performance for the period ending March 31, 2025.
Key Details:
- Conference Call Time: 4:30 p.m. Eastern Time
- Dial-in Numbers: - Domestic: +1 833-470-1428 - International: +1 404-975-4839
- Access Code: 316641
Investors and interested parties can access the live and archived webcast of the event through the company's investor relations website at investor.vicarioussurgical.com. The company's mission focuses on improving lives through the transformation of robotic surgery.
Vicarious Surgical (NYSE: RBOT) has received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards. The company failed to maintain both a 30-day average market capitalization and stockholders' equity above $50 million, with market cap averaging approximately $47.4 million.
The company has 45 days to submit a compliance plan to the NYSE, detailing actions to meet requirements within an 18-month cure period. During this time, RBOT stock will continue trading with a '.BC' (below criteria) designation. If the plan is not submitted timely or accepted, NYSE will initiate delisting proceedings.
The notice does not affect daily operations or SEC reporting obligations. The company is evaluating options to regain compliance with NYSE listing standards.